Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 15.00
-0.12 (-0.79%)
Jul 24, 2026, 5:00 PM CET
Ryvu Therapeutics Financials Overview
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 88.41 | 87.73 | 102.05 | 67.99 | 70.49 | 36.13 |
Revenue Growth | -9.40% | -14.03% | 50.08% | -3.54% | 95.08% | -3.20% |
Gross Profit Gross Profit Growth | 88.41 | 87.73 | 102.05 | 67.99 | 70.49 | 36.13 |
Operating Income Operating Income Growth | -82.08 | -107.61 | -122.1 | -100.95 | -78.42 | -78.6 |
Net Income Net Income Growth | -88.6 | -101.23 | -111.44 | -92.11 | -83.78 | -79.08 |
Earnings Per Share EPS Growth | -3.79 | -4.40 | -4.80 | -4.00 | -4.60 | -4.30 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Poland Poland Growth | 0.08 | 0.06 | 0.04 | 0.11 | 0.16 |
EU Members EU Members Growth | 61.6 | 69.33 | 41.66 | 24.62 | 11.03 |
Other Countries Other Countries Growth | 0.57 | 8.59 | 5.16 | 14.23 | - |
Total Total Growth | 62.25 | 77.97 | 46.86 | 38.95 | 11.19 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 83.11 | 107.68 | 225.93 | 251.15 | 345.41 | 88.23 |
Total Debt Total Debt Growth | 73.64 | 71.72 | 67.11 | 0 | 2.77 | 5.07 |
Net Cash (Debt) Net Cash Growth | 9.46 | 35.96 | 158.83 | 251.15 | 342.64 | 83.16 |
Net Cash Growth | -91.23% | -77.36% | -36.76% | -26.70% | 312.02% | -45.92% |
Net Cash Per Share Net Cash Per Share Growth | 0.41 | 1.56 | 6.87 | 10.97 | 18.67 | 4.53 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -92.76 | -114.1 | -129.48 | -84.55 | 21.32 | -58.89 |
Capital Expenditures CapEx Growth | -7.41 | -7.47 | -5.9 | -8.58 | -1.52 | -11.98 |
Free Cash Flow Free Cash Flow Growth | -100.17 | -121.57 | -135.38 | -93.13 | 19.8 | -70.87 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -92.84% | -122.65% | -119.65% | -148.47% | -111.25% | -217.52% |
Pretax Margin | -92.84% | -115.28% | -108.91% | -135.47% | -112.35% | -218.53% |
Profit Margin | -92.84% | -115.38% | -109.20% | -135.47% | -118.86% | -218.85% |
FCF Margin | -113.30% | -138.57% | -132.67% | -136.97% | 28.09% | -196.13% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 163.70 | 163.70 | 163.70 | 163.70 | 163.70 |
P/FCF Ratio | - | - | - | - | 45.60 | - |
PS Ratio | 3.92 | 7.14 | 17.45 | 19.55 | 12.81 | 30.99 |